Análisis retrospectivo de la continencia urinaria en pacientes sometidos a braquiterapia post-resección transuretral prostática

Claros, Daniel Ramirez; Correia, João Antonio Pereira; Ferreira, Luiz Renato Muglia; Vaz, Fernando Pires

doi:10.1016/s0210-4806(09)74160-9

Cited by 2 publications

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ramirez et al evaluated urinary incontinence in 16 patients with prior TURP and find lower urinary tract symptoms or urinary incontinence after an average of 30 months ( 23 ).…”

Section: Discussionmentioning

confidence: 99%

Low-dose-rate brachytherapy for patients with transurethral resection before implantation in prostate cancer. Long-term results

et al. 2016

View full text Add to dashboard Cite

Objectives We analyzed the long-term oncologic outcome for patients with prostate cancer and transurethral resection who were treated using low-dose-rate (LDR) prostate brachytherapy.Methods and Materials From January 2001 to December 2005, 57 consecutive patients were treated with clinically localized prostate cancer. No patients received external beam radiation. All of them underwent LDR prostate brachytherapy. Biochemical failure was defined according to the “Phoenix consensus”. Patients were stratified as low and intermediate risk based on The Memorial Sloan Kettering group definition.Results The median follow-up time for these 57 patients was 104 months. The overall survival according to Kaplan-Meier estimates was 88% (±6%) at 5 years and 77% (±6%) at 12 years. The 5 and 10 years for failure in tumour-free survival (TFS) was 96% and respectively (±2%), whereas for biochemical control was 94% and respectively (±3%) at 5 and 10 years, 98% (±1%) of patients being free of local recurrence. A patient reported incontinence after treatment (1.7%). The chronic genitourinary complains grade I were 7% and grade II, 10%. At six months 94% of patients reported no change in bowel function.Conclusions The excellent long-term results and low morbidity presented, as well as the many advantages of prostate brachytherapy over other treatments, demonstrates that brachytherapy is an effective treatment for patients with transurethral resection and clinical organ-confined prostate cancer.

show abstract

“…Ramirez et al evaluated urinary incontinence in 16 patients with prior TURP and find lower urinary tract symptoms or urinary incontinence after an average of 30 months ( 23 ).…”

Section: Discussionmentioning

confidence: 99%

Low-dose-rate brachytherapy for patients with transurethral resection before implantation in prostate cancer. Long-term results

et al. 2016

View full text Add to dashboard Cite

show abstract

A history of transurethral resection of the prostate should not be a contra-indication for low-dose-rate 125I prostate brachytherapy: results of a prospective Uro-GEC phase-II trial

Salembier¹,

Henry²,

Pieters³

et al. 2020

jcb

View full text Add to dashboard Cite

Purpose: Early reports suggested that transurethral resection (TURP) prior to permanent seed brachytherapy (BT) results in high incontinence rates. Guidelines consider prior TURP as a contra-indication to treatment, but improvements in imaging and treatment planning may reduce this risk, and are investigated in this prospective study. Material and methods: 99 men with histologically proven low-to intermediate-risk, localized prostate cancer, with a history of TURP performed at least 3 months before BT procedure were enrolled. All patients received a permanent seed implant between March 2009 and June 2015. Intra-operative interactive planning was recommended to ensure optimal accuracy of seed placement during the procedure. No supplemental external beam was allowed. Target and organ at risk contouring, definition of clinical target volume (CTV), and dosimetric parameters followed the modified GEC-ESTRO guidelines for permanent seed implants, as described an earlier report of our group. Follow-up was scheduled every 3 months for the first year, and every 6 months afterwards, with minimum follow-up of 2 years. Study endpoints: The primary endpoint was the incidence of post-implant urinary incontinence. Secondary endpoints were the incidence of urinary and gastro-intestinal toxicity, the eventual impact on the sexual function, and the freedom from biochemical failure. Results: The median follow-up time for these 99 patients was 49 months (min. 24, max. 96). In this series, the incontinence rate was 2% after TURP + BT and 2% in case of TURP + BT + re-TURP, ending up with a total urinary incontinence rate of 4%. Acute and late urinary toxicities were extremely low. No significant late gastro-intestinal toxicity was seen, and the 5-year biochemical non-evidence of disease (bNED) was 93%. Conclusions: The excellent long-term results and low morbidity presented as well as many advantages of prostate brachytherapy over other treatments demonstrates that brachytherapy is an effective treatment for patients with transurethral resection and organ-confined prostate cancer.

show abstract

Análisis retrospectivo de la continencia urinaria en pacientes sometidos a braquiterapia post-resección transuretral prostática

Abstract: In accordance with other studies, we believe that with some strategy TURP should not be considered a relative contra-indication for brachytherapy.

Cited by 2 publications

References 22 publications

Low-dose-rate brachytherapy for patients with transurethral resection before implantation in prostate cancer. Long-term results

Low-dose-rate brachytherapy for patients with transurethral resection before implantation in prostate cancer. Long-term results

A history of transurethral resection of the prostate should not be a contra-indication for low-dose-rate 125I prostate brachytherapy: results of a prospective Uro-GEC phase-II trial

Contact Info

Product

Resources

About